1/79
Looks like no tags are added yet.
Androgen insensitivity syndrome (AIS) - Clinical Vignette
A 16-year-old with female external genitalia and primary amenorrhea is found to have a blind-ending vagina and absent uterus. Karyotype is 46,XY. Testes are identified in the inguinal canal.
Androgen insensitivity syndrome (AIS) - Genetics
X-linked recessive inheritance caused by hemizygous loss-of-function variants in AR (Xq12) encoding the androgen receptor (primarily missense variants in the androgen-binding or DNA-binding zinc-finger domains, or exon 1 truncations/deletions). Phenotype correlates with residual receptor transactivation: Complete AIS (CAIS, female external genitalia and primary amenorrhea), Partial AIS (PAIS, ambiguous/undervirilized genitalia), and Mild AIS (male phenotype with infertility and gynecomastia; allelic with X-linked CAG-repeat spinal and bulbar muscular atrophy / Kennedy disease).
Androgen insensitivity syndrome (AIS) - Key Features
Complete AIS (CAIS) in a 46,XY individual: unambiguous female external genitalia and female gender identity presenting with primary amenorrhea in adolescence or bilateral inguinal hernias/masses (testes) in infancy Absent uterus, cervix, and upper vagina with a blind-ending vaginal pouch (fetal Sertoli cells produce normal anti-Mullerian hormone, causing Mullerian regression) Normal pubertal breast development (peripheral aromatization of elevated testicular testosterone into estradiol) Absent or sparse pubic and axillary hair ("hairless" adrenarche/pubarche due to end-organ androgen resistance) and tall-normal female stature.
Androgen insensitivity syndrome (AIS) - Diagnosis
46,XY karyotype in a phenotypic female (or individual with undervirilized/ambiguous genitalia) Hormone profile showing normal-to-elevated male-range serum testosterone, normal-to-elevated LH, normal testosterone-to-DHT ratio (excluding 5-alpha-reductase deficiency), and detectable AMH Pelvic ultrasound or MRI confirming absent Mullerian structures (uterus and fallopian tubes) and intra-abdominal or inguinal testes Molecular confirmation via AR gene sequencing and deletion/duplication analysis.
Androgen insensitivity syndrome (AIS) - Management
Bilateral gonadectomy due to increased postpubertal testicular germ cell tumor risk (in CAIS, often deferred until after spontaneous estrogen-driven pubertal breast development and final height attainment, with surveillance if retained) Lifelong estrogen replacement therapy (without progestin, as there is no uterus) after gonadectomy to maintain secondary sexual characteristics and bone mineral density Vaginal dilation (first-line) or vaginoplasty if desired for vaginal hypoplasia Multidisciplinary psychosocial support and X-linked genetic counseling
Aromatase deficiency - Clinical Vignette
A 46,XX newborn presents with ambiguous genitalia (virilized female). The mother experienced progressive virilization during pregnancy (deepening voice, acne, hirsutism). At puberty, the patient fails to develop breasts and has primary amenorrhea with hypergonadotropic hypogonadism and tall stature.
Aromatase deficiency - Genetics
Autosomal recessive inheritance caused by biallelic loss-of-function variants in CYP19A1 encoding aromatase (cytochrome P450aro), the enzyme that converts C19 androgens (androstenedione, testosterone, and 16-alpha-hydroxy-DHEAS) into estrogens (estrone, estradiol, and estriol) in the placenta, gonads, bone, and adipose tissue. Loss of placental aromatase during gestation leaves fetal adrenal androgens unconverted, virilizing both a 46,XX fetus and the pregnant mother.
Aromatase deficiency - Key Features
46,XX DSD with virilized/ambiguous female external genitalia at birth (normal internal Mullerian uterus and ovaries) Progressive maternal virilization during the second/third trimester of pregnancy (acne, hirsutism, clitoromegaly, irreversible voice deepening) that resolves postpartum (classic diagnostic clue, shared with POR deficiency) Pubertal failure in 46,XX females: absent breast development, primary amenorrhea, progressive virilization, hypergonadotropic hypogonadism, and enlarged multicystic ovaries Tall eunuchoid stature with markedly delayed bone age, unfused epiphyses, and osteopenia/osteoporosis in both 46,XX and 46,XY individuals (estrogen is required for epiphyseal fusion and bone mineralization in both sexes).
Aromatase deficiency - Diagnosis
Endocrine profile showing undetectable/very low serum estradiol and estrone paired with elevated testosterone, androstenedione, FSH, and LH Characteristic history of maternal virilization during gestation alongside delayed bone age on radiographs and multicystic ovaries on pelvic ultrasound Molecular genetic confirmation via CYP19A1 sequencing.
Aromatase deficiency - Management
Low-dose graduated estrogen replacement at puberty in 46,XX patients (transitioned to cyclic estrogen-progestin therapy) to induce breast development, normal menses, ovarian cyst regression, bone accrual, and epiphyseal closure Low-dose estradiol replacement in affected 46,XY males to promote epiphyseal closure, normalize bone mineral density, and correct lipid/insulin metabolism Reconstructive surgical options as appropriate for severe genital virilization and genetic counseling for 25% autosomal recessive recurrence risk
Congenital adrenal hyperplasia (21-hydroxylase deficiency) - Clinical Vignette
A newborn female has ambiguous genitalia with clitoromegaly and labial fusion. She develops a salt-wasting crisis at 2 weeks of age with hyponatremia and hyperkalemia.
Congenital adrenal hyperplasia (21-hydroxylase deficiency) - Genetics
Autosomal recessive inheritance caused by biallelic loss-of-function variants in CYP21A2 (~95% of all CAH), largely arising via unequal crossover (30-kb chimeric deletion) or micro/macro-gene conversions with the adjacent 98%-homologous pseudogene CYP21A1P. Impaired adrenal 21-hydroxylase blocks conversion of progesterone and 17-hydroxyprogesterone (17-OHP) to aldosterone and cortisol, losing negative feedback on ACTH (causing adrenal hyperplasia) and shunting accumulated precursors into adrenal androgens. Severity follows the milder allele's residual enzyme activity: classic salt-wasting (0% null alleles), classic simple virilizing (~2-11%, e.g., p.Ile173Asn), and mild late-onset non-classic (~20-50%, e.g., p.Val282Leu).
Congenital adrenal hyperplasia (21-hydroxylase deficiency) - Key Features
Prenatal virilization and ambiguous genitalia (clitoromegaly, labioscrotal fusion, urogenital sinus) in classic 46,XX females with normal internal uterus/ovaries Normal-appearing male external genitalia at birth in 46,XY infants (risking missed diagnosis without newborn screening, followed by life-threatening salt-wasting crisis or early peripheral precocious puberty) Neonatal adrenal salt-wasting crisis at 1-3 weeks of life (~75% of classic cases): poor feeding, vomiting, severe dehydration, hyponatremia, hyperkalemia, metabolic acidosis, hypoglycemia, and hypovolemic shock Non-classic late-onset form: premature pubarche, advanced bone age, hirsutism, acne, oligomenorrhea, and subfertility mimicking PCOS.
Congenital adrenal hyperplasia (21-hydroxylase deficiency) - Diagnosis
Markedly elevated basal serum 17-hydroxyprogesterone (17-OHP; included universally on the Recommended Uniform Screening Panel newborn screen) Cosyntropin (ACTH) stimulation testing demonstrating an exaggerated rise in 17-OHP for borderline or non-classic cases, alongside serum electrolytes, low aldosterone, and elevated plasma renin activity CYP21A2 molecular genetic testing (specialized sequencing + MLPA/deletion-conversion analysis, testing parents to phase complex gene conversions across alleles).
Congenital adrenal hyperplasia (21-hydroxylase deficiency) - Management
Lifelong glucocorticoid replacement (hydrocortisone in growing children to avoid growth suppression) to replace cortisol and suppress excess ACTH-driven androgen production, with immediate parenteral stress-dose hydrocortisone during febrile illness, trauma, or surgery Mineralocorticoid replacement (fludrocortisone) plus oral sodium chloride supplementation in infants with classic salt-wasting disease Multidisciplinary DSD care, growth/bone-age monitoring, and genetic counseling for 25% autosomal recessive recurrence risk
SRY translocation (46,XX testicular DSD) - Clinical Vignette
A phenotypically male adult presents with infertility and small testes. Karyotype reveals 46,XX. FISH shows the SRY gene translocated to one X chromosome. The patient has male external genitalia, no uterus, and azoospermia.
SRY translocation (46,XX testicular DSD) - Genetics
Usually sporadic / de novo arising from aberrant unequal recombination between the X and Y pseudoautosomal/adjacent regions during paternal meiosis I, transferring a distal Yp fragment containing SRY (sex-determining region Y) onto the short arm of the paternal X chromosome (~80% of 46,XX testicular DSD is SRY-positive; ~20% is SRY-negative, e.g., SOX9 duplications). Presence of SRY activates SOX9 and drives testicular differentiation in a 46,XX zygote, while absence of the long-arm Yq AZF spermatogenesis loci causes universal azoospermia.
SRY translocation (46,XX testicular DSD) - Key Features
Normal male external genitalia in most SRY-positive individuals (ambiguous genitalia/hypospadias is more common in SRY-negative 46,XX testicular DSD) Small, firm postpubertal testes and non-obstructive azoospermia (100% infertile due to absence of Yq AZF genes) Absence of uterus and fallopian tubes (normal embryonic Sertoli cell AMH secretion) Hypergonadotropic hypogonadism in adulthood (low-normal or low testosterone with elevated FSH/LH), variable gynecomastia, and normal-to-short male stature (shorter than 46,XY males and Klinefelter 47,XXY males due to absence of Y-chromosome stature genes).
SRY translocation (46,XX testicular DSD) - Diagnosis
Standard peripheral blood karyotype demonstrating 46,XX in a phenotypic male (distinguishing it from 47,XXY Klinefelter syndrome) Fluorescence in situ hybridization (FISH) or chromosomal microarray confirming the presence and chromosomal location of SRY (typically on Xp) Semen analysis showing azoospermia and endocrine labs showing elevated FSH/LH with normal-to-low testosterone.
SRY translocation (46,XX testicular DSD) - Management
Testosterone replacement therapy if biochemical/clinical hypogonadism develops to maintain virilization, libido, energy, and bone mineral density Fertility counseling explaining that testicular sperm extraction (TESE) will not succeed because the Yq AZF spermatogenesis loci are completely absent (donor sperm IUI/IVF or adoption are reproductive options) Surgical reduction mammoplasty if bothersome gynecomastia occurs Genetic counseling reassuring parents that SRY-on-X translocation is almost always a de novo paternal meiotic event with negligible sibling recurrence risk
X-linked adrenal hypoplasia congenita (AHC) - Clinical Vignette
A male infant presents in the first weeks of life with vomiting, hyponatremia, hyperkalemia, and shock. Cortisol and aldosterone are low. ACTH is markedly elevated. Years later, he fails to enter puberty: gonadotropins are inappropriately low. A maternal uncle died of "adrenal crisis" in infancy.
X-linked adrenal hypoplasia congenita (AHC) - Genetics
X-linked recessive inheritance caused by hemizygous loss-of-function variants or deletions (~25%) in NR0B1 (Xp21.2) encoding the orphan nuclear receptor DAX1, which regulates progenitor development in both the adrenal cortex and the hypothalamic-pituitary-gonadal axis. Larger Xp21 contiguous gene deletions removing NR0B1 along with neighboring GK and DMD cause a classic contiguous syndrome of AHC + glycerol kinase deficiency (pseudohypertriglyceridemia) + Duchenne muscular dystrophy.
X-linked adrenal hypoplasia congenita (AHC) - Key Features
Primary salt-wasting adrenal insufficiency in affected males (classic bimodal onset in the first 2 months of life or later in childhood): vomiting, dehydration, hyponatremia, hyperkalemia, hypoglycemia, hyperpigmentation, and shock Normal male external genitalia at birth AND normal/low 17-hydroxyprogesterone (critical distinction from 21-hydroxylase CAH; AHC is missed on 17-OHP newborn screening) Hypogonadotropic hypogonadism at puberty (mixed hypothalamic and pituitary GnRH/gonadotropin deficiency causing absent or arrested puberty) Intrinsic primary Sertoli/germ-cell defect causing azoospermia that typically fails to respond even to exogenous gonadotropin therapy.
X-linked adrenal hypoplasia congenita (AHC) - Diagnosis
Biochemical primary adrenal insufficiency (low cortisol, low aldosterone, markedly elevated ACTH and plasma renin activity) with normal or low 17-OHP and adrenal androgens (excluding 21-hydroxylase CAH) and hypoplastic/absent adrenals on imaging Serum creatine kinase (CK) and fasting triglycerides/urine glycerol in male infants to screen for an Xp21 contiguous gene deletion involving DMD and GK Molecular confirmation via NR0B1 sequencing and deletion/duplication analysis (or chromosomal microarray if contiguous deletion is suspected).
X-linked adrenal hypoplasia congenita (AHC) - Management
Lifelong glucocorticoid (hydrocortisone) and mineralocorticoid (fludrocortisone) replacement with salt supplementation in infancy and sick-day stress-dose glucocorticoid protocols Pubertal induction and maintenance in adolescence using exogenous testosterone replacement Fertility counseling addressing intrinsic spermatogenic failure (often refractory to hCG/FSH gonadotropins, though TESE-ICSI has rarely been attempted; donor sperm or adoption discussed) X-linked genetic counseling and maternal/female relative carrier testing to enable immediate postnatal steroid monitoring of at-risk newborn boys
Maturity-onset diabetes of the young (MODY) - Clinical Vignette
A thin 18-year-old is diagnosed with diabetes without ketosis. He has negative islet autoantibodies. His mother and grandfather both developed diabetes before age 25.
Maturity-onset diabetes of the young (MODY) - Genetics
Autosomal dominant monogenic non-autoimmune beta-cell diabetes (>14 genes; GCK and HNF1A together account for the vast majority): GCK (MODY 2, glucokinase glucose-sensor defect raising the glycemic threshold for regulated insulin secretion), HNF1A (MODY 3) and HNF4A (MODY 1, hepatocyte nuclear transcription factors causing progressive beta-cell insulin secretory failure), and HNF1B (MODY 5, 17q12 whole-gene deletions in ~50% or intragenic variants causing renal cysts and diabetes syndrome).
Maturity-onset diabetes of the young (MODY) - Key Features
Early-onset non-ketotic diabetes mellitus (typically diagnosed before age 25-35 years) in a non-obese individual without acanthosis nigricans or insulin resistance Multigenerational autosomal dominant family history of early-onset diabetes Negative pancreatic islet autoantibodies (GAD65, IA-2, ZnT8) and preserved measurable endogenous C-peptide (distinguishing MODY from Type 1 diabetes) Subtype-specific hallmarks: lifelong mild stable asymptomatic fasting hyperglycemia (~100-145 mg/dL) without microvascular complications in GCK-MODY; low renal threshold glycosuria in HNF1A-MODY; transient neonatal hyperinsulinemic hypoglycemia and macrosomia preceding later diabetes in HNF4A-MODY; renal cysts/dysplasia, Mullerian uterine anomalies, hypomagnesemia, and hyperuricemia/gout in HNF1B-MODY.
Maturity-onset diabetes of the young (MODY) - Diagnosis
Clinical suspicion in young (<35 years), non-obese, islet-autoantibody-negative diabetes with preserved C-peptide and a 2-to-3-generation autosomal dominant family history Comprehensive multigene MODY sequencing and deletion/duplication panel (including 17q12/HNF1B copy-number coverage), as molecular subtyping directly alters clinical management.
Maturity-onset diabetes of the young (MODY) - Management
GCK-MODY (MODY 2): discontinue oral hypoglycemics and insulin outside of pregnancy (pharmacotherapy does not lower HbA1c, and complications are rare; during pregnancy, maternal insulin therapy depends on whether the fetus inherited the GCK variant and fetal ultrasound growth) HNF1A-MODY (MODY 3) and HNF4A-MODY (MODY 1): first-line low-dose oral sulfonylureas (act at the KATP channel downstream of the metabolic transcription defect, allowing safe transition off misdiagnosed insulin) HNF1B-MODY (MODY 5): insulin therapy typically required, paired with nephrology, urologic/gynecologic, and electrolyte (magnesium/uric acid) surveillance Cascade genetic testing of affected and at-risk first-degree relatives
Transient neonatal diabetes mellitus - Clinical Vignette
A newborn with severe IUGR develops hyperglycemia in the first week of life requiring insulin. Diabetes resolves by 12 weeks but recurs in adolescence.
Transient neonatal diabetes mellitus - Genetics
Caused in ~70% of cases by an imprinting defect at 6q24 resulting in double dosage/overexpression of paternally expressed genes PLAGL1 and HYMAI via three mechanisms: paternal uniparental disomy of chromosome 6 (~41%, mostly isodisomy), paternally inherited or de novo 6q24 duplication (~29%), or maternal allele hypomethylation (~30%, isolated or due to autosomal recessive ZFP57 multilocus imprinting disturbance). Most remaining cases (~25%) are autosomal dominant activating variants in KCNJ11 (Kir6.2) or ABCC8 (SUR1) encoding subunits of the pancreatic beta-cell KATP channel.
Transient neonatal diabetes mellitus - Key Features
Severe intrauterine growth restriction (IUGR / low birth weight, reflecting fetal insulin deficiency in utero) Severe non-ketotic hyperglycemia presenting within the first week (or first 6 weeks) of life Spontaneous remission of insulin requirement in infancy (typically by 3-18 months of age; median ~12 weeks in 6q24 TNDM) High rate (~50-80%) of permanent or intermittent non-autoimmune diabetes relapse later in adolescence, adulthood, or during pregnancy (plus occasional macroglossia or umbilical hernia in 6q24 cases).
Transient neonatal diabetes mellitus - Diagnosis
Persistent insulin-requiring hyperglycemia presenting in the first weeks of life (all diabetes diagnosed before 6 months of age warrants immediate monogenic neonatal diabetes testing rather than Type 1 diabetes labeling) DNA methylation and copy-number/UPD analysis of the imprinted 6q24 locus (plus ZFP57 testing if maternal hypomethylation is found) Sequencing of KCNJ11 and ABCC8 to identify sulfonylurea-responsive KATP channelopathies.
Transient neonatal diabetes mellitus - Management
Carefully titrated insulin replacement and high-calorie nutritional rehabilitation during the acute neonatal hyperglycemic phase until spontaneous remission occurs Transition from insulin to oral high-dose sulfonylureas for patients harboring activating KCNJ11 or ABCC8 variants Lifelong annual glycemic/HbA1c surveillance after remission (especially during puberty and pregnancy) to detect and treat diabetes relapse (often responsive to oral agents or sulfonylureas) Mechanism-specific genetic counseling (low recurrence risk in de novo UPD6 vs 50% paternal transmission risk in paternal 6q24 duplication or AD KCNJ11/ABCC8 vs 25% AR risk in ZFP57)
Wolfram syndrome (DIDMOAD) - Clinical Vignette
A teenager with type 1 diabetes is found to have progressive vision loss (optic atrophy). Audiometry reveals sensorineural hearing loss. Urological workup shows diabetes insipidus.
Wolfram syndrome (DIDMOAD) - Genetics
Autosomal recessive endoplasmic reticulum stress disorder caused by biallelic loss-of-function variants in WFS1 (>90%, encoding the ER transmembrane glycoprotein wolframin, which regulates ER calcium homeostasis and the unfolded protein response; heterozygous WFS1 variants can cause milder AD nonclassic optic atrophy/deafness). Rare Wolfram syndrome type 2 is caused by biallelic variants in CISD2 (adds peptic ulcer bleeding/platelet defect without diabetes insipidus).
Wolfram syndrome (DIDMOAD) - Key Features
Classic "DIDMOAD" tetrad: Diabetes Insipidus (central/neurohypophyseal vasopressin deficiency, typically 2nd decade) Diabetes Mellitus (juvenile-onset, insulin-dependent, islet-autoantibody-negative beta-cell degeneration, usually the earliest feature around age ~6 years) Optic Atrophy (progressive bilateral loss of color and central/peripheral vision presenting at median age ~11 years) Deafness (progressive bilateral high-frequency sensorineural hearing loss) Neurogenic bladder / urinary tract dilation (hydroureteronephrosis) and progressive brainstem/cerebellar atrophy causing ataxia, central apnea, dysphagia, and psychiatric depression.
Wolfram syndrome (DIDMOAD) - Diagnosis
Clinical suspicion in any child or adolescent with early-onset non-autoimmune (antibody-negative) insulin-dependent diabetes mellitus who develops bilateral optic atrophy (the minimal clinical diagnostic dyad) Ophthalmologic OCT/fundoscopy, pure-tone audiometry, water-deprivation/serum-urine osmolality testing, renal/bladder ultrasound, and brain MRI (showing absent posterior pituitary bright spot and brainstem/cerebellar atrophy) Molecular confirmation via WFS1 (and CISD2) sequencing and deletion/duplication analysis.
Wolfram syndrome (DIDMOAD) - Management
Multidisciplinary supportive management across endocrinology, ophthalmology, audiology, urology, neurology, and psychiatry Insulin replacement therapy for diabetes mellitus and intranasal/oral desmopressin (DDAVP) for central diabetes insipidus Low-vision rehabilitation and hearing aids or cochlear implants for progressive dual sensory loss Urodynamic surveillance, anticholinergics, or clean intermittent catheterization for neurogenic bladder, plus genetic counseling for 25% autosomal recessive recurrence risk
Kallmann syndrome - Clinical Vignette
A 17-year-old male has not entered puberty. He has anosmia (cannot smell). MRI shows hypoplastic olfactory bulbs.
Kallmann syndrome - Genetics
Genetically heterogeneous congenital GnRH deficiency with defective embryonic co-migration of olfactory axons and GnRH-secreting neurons from the nasal olfactory placode across the cribriform plate to the hypothalamus: X-linked recessive (ANOS1, formerly KAL1, encoding cell-adhesion protein anosmin-1; ~8%), autosomal dominant with incomplete penetrance (FGFR1 ~10%, FGF8, CHD7 overlapping with CHARGE syndrome), autosomal recessive, and oligogenic (~10-15% carry pathogenic variants in >=2 genes such as PROK2/PROKR2).
Kallmann syndrome - Key Features
Congenital hypogonadotropic hypogonadism (absent or arrested puberty, micropenis and cryptorchidism in male infants, primary amenorrhea in females, infertility, and low bone mineral density) Congenital complete anosmia or severe hyposmia (distinguishes Kallmann syndrome from normosmic isolated hypogonadotropic hypogonadism) Gene-associated non-reproductive anomalies: unilateral renal agenesis (~30%) and bimanual mirror movements / synkinesia (~80%) in X-linked ANOS1; cleft lip/palate, dental agenesis, and digital anomalies in FGFR1/FGF8; ear anomalies, coloboma, or hearing loss in CHD7.
Kallmann syndrome - Diagnosis
Biochemical hypogonadotropic hypogonadism: low serum testosterone or estradiol paired with inappropriately low or low-normal LH and FSH (with otherwise normal anterior pituitary function) Formal quantitative olfactory smell identification testing confirming anosmia/hyposmia plus brain MRI showing absent or hypoplastic olfactory bulbs and sulci Multigene panel sequencing (ANOS1, FGFR1, FGF8, PROK2, PROKR2, CHD7, SOX10, and others) accompanied by renal ultrasound, audiometry, and baseline DEXA bone scan.
Kallmann syndrome - Management
Pubertal induction and maintenance hormone replacement: exogenous testosterone in males or graduated estradiol followed by cyclic estrogen-progestin in females (supports secondary sexual characteristics and bone density, though sex steroids alone do not stimulate spermatogenesis) Fertility restoration when pregnancy is desired using pulsatile subcutaneous GnRH pump therapy or combined gonadotropin injections (hCG + recombinant FSH; unlike primary testicular failure, fertility is frequently restorable) Infant orchiopexy (and short-course testosterone/gonadotropins for micropenis) plus inheritance-specific genetic counseling (X-linked, AD, AR, or oligogenic)
Male infertility (genetic causes) - Clinical Vignette
A 32-year-old man with primary infertility for 2 years has azoospermia on two semen analyses, normal LH/FSH/testosterone, and normal testicular volume. Karyotype is 46,XY. Y chromosome microdeletion testing reveals an AZFc deletion. Counseling covers the option of testicular sperm extraction with ICSI and the certainty that any resulting sons will inherit the same AZFc deletion and infertility.
Male infertility (genetic causes) - Genetics
Etiologically heterogeneous across chromosomal, Y-microdeletion, and monogenic mechanisms: (1) Klinefelter syndrome (47,XXY, most common chromosomal cause, ~10-15% of non-obstructive azoospermia) and balanced reciprocal/Robertsonian translocations (~5%); (2) Yq11 Azoospermia Factor (AZF) recurrent microdeletions mediated by homologous recombination (most common molecular cause of non-obstructive azoospermia/severe oligospermia: AZFa causes Sertoli-cell-only, AZFb causes spermatocyte maturation arrest, AZFc causes variable severe oligospermia/azoospermia); (3) CFTR variants (often one severe allele in trans with the intron 8 5T/TG12-13 allele) causing obstructive azoospermia via congenital bilateral absence of the vas deferens (CBAVD); and (4) hypothalamic-pituitary GnRH genes (ANOS1, FGFR1) or mild AR variants.
Male infertility (genetic causes) - Key Features
Non-obstructive azoospermia or severe oligospermia (<5 million/mL) due to primary spermatogenic failure: small testes and elevated FSH in 47,XXY Klinefelter or AZFa/b deletions, or normal-to-mildly reduced testicular volume in AZFc deletions Obstructive azoospermia due to CBAVD (CFTR): normal testicular volume, normal FSH/LH/testosterone, intact spermatogenesis, low-volume acidic fructose-negative ejaculate, and non-palpable vasa deferentia Pre-testicular hypogonadotropic azoospermia (Kallmann/CHH): low testosterone with low/inappropriately normal FSH and LH.
Male infertility (genetic causes) - Diagnosis
Two centrifuged semen analyses confirming azoospermia or severe oligospermia paired with physical genital exam (testicular volume, presence of vas deferens) and morning FSH, LH, and total testosterone Peripheral blood G-banded karyotype PLUS PCR-based Y-chromosome AZF microdeletion testing (AZFa, AZFb, AZFc; submicroscopic AZF deletions are invisible on standard karyotype) for all men with non-obstructive azoospermia or severe oligospermia (<5 million/mL) Comprehensive CFTR sequencing + intron 8 5T/TG tract genotyping (plus mandatory female partner CFTR carrier screening) for men with obstructive CBAVD.
Male infertility (genetic causes) - Management
Genotype-guided surgical sperm retrieval with IVF/ICSI: microdissection testicular sperm extraction (microTESE) often succeeds in AZFc deletions (~50-70%) and young 47,XXY patients, whereas complete AZFa or AZFb deletions have virtually zero sperm retrieval and warrant counseling toward donor sperm or adoption Epididymal or testicular sperm aspiration with IVF/ICSI for CFTR-related CBAVD after testing the female partner for CFTR carrier status (offering PGT-M if both partners carry CFTR variants) Pulsatile GnRH or gonadotropin (hCG + FSH) therapy to restore endogenous spermatogenesis in hypogonadotropic hypogonadism (Kallmann syndrome) Genetic counseling emphasizing 100% vertical Y-linked transmission of AZFc microdeletions (and infertility) to all biological sons conceived via ICSI, or PGT-SR for balanced translocation carriers
Hutchinson-Gilford progeria - Clinical Vignette
A 5-year-old has severe growth failure, alopecia, and aged appearance with thin skin and prominent veins. Cardiac workup reveals severe atherosclerosis.
Hutchinson-Gilford progeria - Genetics
Autosomal dominant inheritance, arising de novo in virtually all cases (low ~1-2% sibling recurrence risk from parental germline mosaicism). Classic HGPS (~90%) is caused by a recurrent de novo synonymous substitution in exon 11 of LMNA—c.1824C>T (p.Gly608Gly)—which activates a cryptic splice donor site, deleting 50 amino acids including the ZMPSTE24 endoprotease cleavage site. The resulting mutant protein ("progerin") retains its C-terminal farnesyl lipid anchor and remains permanently tethered to the inner nuclear membrane, causing nuclear blebbing and toxic dominant-negative/gain-of-function cellular senescence.
Hutchinson-Gilford progeria - Key Features
Normal appearance at birth followed by severe postnatal growth failure, sclerodermatous skin tightening, and loss of subcutaneous adipose tissue (lipodystrophy) starting at 6-24 months Characteristic progeroid craniofacial gestalt: total alopecia (scalp, eyebrows, eyelashes), prominent scalp veins, craniofacial disproportion, micrognathia, delayed dental eruption, and high-pitched voice Skeletal anomalies: acro-osteolysis of distal phalanges, clavicular resorption, coxa valga, and progressive joint contractures WITH completely normal intellectual/cognitive development Severe accelerated premature vascular stiffening and generalized atherosclerosis leading to transient ischemic attacks, strokes, myocardial infarction, and early mortality in the mid-to-late teens.
Hutchinson-Gilford progeria - Diagnosis
Clinical recognition of profound postnatal growth failure, alopecia, lipodystrophy, and characteristic progeroid facies with preserved cognition in early childhood Targeted molecular genetic testing for the recurrent LMNA c.1824C>T (p.Gly608Gly) variant (followed by full LMNA/ZMPSTE24 sequencing for nonclassic progeroid laminopathies) Baseline and serial echocardiography, carotid ultrasound, and brain/head-and-neck MRA to evaluate premature occlusive cerebrovascular and coronary disease.
Hutchinson-Gilford progeria - Management
Oral lonafarnib (farnesyltransferase inhibitor that blocks toxic farnesylation and nuclear membrane accumulation of progerin, reducing vascular stiffness and extending survival) Cardiovascular and stroke risk mitigation including low-dose aspirin antiplatelet prophylaxis, optimal hydration, and blood pressure/lipid monitoring Frequent high-calorie nutrient-dense meals, physical/occupational therapy for joint contractures, dental care for crowding, and routine schooling (given normal intelligence) Genetic counseling reassuring parents of de novo occurrence with a small (~1-2%) theoretical risk of parental gonadal mosaicism
Seckel syndrome - Clinical Vignette
A child with severe proportionate short stature has a "bird-like" face with a prominent beaked nose and receding forehead. Microcephaly is severe with intellectual disability.
Seckel syndrome - Genetics
Autosomal recessive microcephalic primordial dwarfism with locus heterogeneity across DNA-damage-response and centrosomal/mitotic-spindle genes: ATR (encoding ataxia-telangiectasia and Rad3-related kinase that senses replication stress; viable Seckel alleles are hypomorphic splice/missense variants rather than lethal complete nulls), ATRIP, RBBP8 (CtIP), CENPJ, CEP152, CEP63, NIN, and DNA2 (with phenotypic overlap with PCNT-related MOPD II). Slowed embryonic cell-cycle progression and premature neuroprogenitor depletion reduce total cell number, disproportionately affecting cerebral cortical size.
Seckel syndrome - Key Features
Severe intrauterine growth restriction and proportionate postnatal dwarfism (weight, length, and head circumference far below the 1st percentile) Severe progressive congenital microcephaly (often -4 to -10 SD) with simplified cortical gyral pattern and moderate-to-severe intellectual disability Characteristic "bird-headed" craniofacial profile: sloping/receding forehead, large prominent eyes, prominent convex/beaked nose, narrow face, and severe micrognathia Skeletal findings (fifth-finger clinodactyly, radial head dislocation, 11 pairs of ribs, hip dysplasia) and occasional bone marrow failure/pancytopenia or myelodysplasia.
Seckel syndrome - Diagnosis
Clinical and radiographic recognition of severe proportionate prenatal/postnatal primordial growth restriction paired with disproportionate microcephaly and characteristic facial profile Multigene microcephalic primordial dwarfism sequencing panel (ATR, RBBP8, CENPJ, CEP152, CEP63, NIN, ATRIP, PCNT) Brain MRI (evaluating simplified gyration/corpus callosum anomalies), skeletal survey, and baseline CBC.
Seckel syndrome - Management
Multidisciplinary developmental, speech, physical, and special educational support Nutritional optimization and orthopedic management of hip dysplasia or radial head dislocation Periodic CBC monitoring for cytopenias or bone marrow failure in DNA-repair-associated subtypes Genetic counseling regarding autosomal recessive inheritance (25% sibling recurrence risk)
Simpson-Golabi-Behmel syndrome - Clinical Vignette
A macrosomic male newborn has coarse facial features, a large tongue, and supernumerary nipples. He has developmental delay and renal anomalies.
Simpson-Golabi-Behmel syndrome - Genetics
X-linked inheritance caused by hemizygous loss-of-function sequence variants or intragenic/whole-gene deletions (~43% of pathogenic alleles, sometimes extending contiguously into neighboring GPC4) in GPC3 (Xq26.2), encoding glypican-3, a GPI-anchored cell-surface heparan sulfate proteoglycan that modulates Hedgehog, Wnt, BMP, and FGF growth signaling. Primarily affects males (~9:1 male predominance), while heterozygous females range from asymptomatic to fully affected due to skewed X-inactivation.
Simpson-Golabi-Behmel syndrome - Key Features
Prenatal and postnatal macrosomia / somatic overgrowth (phenotypically overlapping with Beckwith-Wiedemann syndrome) Coarse "bulldog-like" craniofacial features: macrocephaly, hypertelorism, broad flat nasal bridge, macrostomia, macroglossia, midline lower-lip groove, and cleft lip/palate Supernumerary nipples, pectus excavatum, broad short hands/nails, and postaxial polydactyly or cutaneous syndactyly Congenital visceral malformations: congenital heart defects (~35%), congenital diaphragmatic hernia, nephromegaly/renal dysplasia, and cryptorchidism Variable developmental delay / intellectual disability (normal to severe) and ~7-10% childhood risk of embryonal tumors (Wilms tumor, hepatoblastoma, neuroblastoma, gonadoblastoma).
Simpson-Golabi-Behmel syndrome - Diagnosis
Clinical recognition of pre- and postnatal overgrowth, coarse facies, macroglossia, and supernumerary nipples in a male (after distinguishing from 11p15.5 Beckwith-Wiedemann syndrome) Molecular confirmation via GPC3 sequencing AND mandatory deletion/duplication analysis (as exon/whole-gene deletions account for >40% of cases) Baseline echocardiogram, abdominal/renal ultrasound, and neonatal blood glucose monitoring.
Simpson-Golabi-Behmel syndrome - Management
Childhood embryonal tumor surveillance (following Beckwith-Wiedemann-style protocols): abdominal/renal ultrasound every 3 months until age 7-8 years (for Wilms tumor and hepatoblastoma) and serial serum alpha-fetoprotein (AFP) in early childhood Neonatal hypoglycemia screening and airway/feeding/surgical management for macroglossia, cleft palate, congenital heart defects, and diaphragmatic hernia Developmental and educational therapies X-linked genetic counseling and maternal carrier testing (noting variable expression in carrier females)
PIK3CA-related overgrowth spectrum - Clinical Vignette
A child has asymmetric overgrowth affecting one leg with vascular malformations and epidermal nevi. Tissue biopsy reveals a somatic PIK3CA variant.
PIK3CA-related overgrowth spectrum - Genetics
Postzygotic somatic mosaicism (not inherited) caused by activating gain-of-function missense variants in PIK3CA encoding p110-alpha, the catalytic subunit of phosphatidylinositol-3-kinase, leading to constitutive PI3K-AKT-mTOR pathway activation in mutant cell lineages. Strong cancer-associated hotspot variants (p.Glu542Lys, p.Glu545Lys, p.His1047Arg) cause severe focal/truncal syndromes (CLOVES, Klippel-Trenaunay, fibroadipose hyperplasia, isolated hemimegalencephaly), whereas milder non-hotspot variants with broader embryonic mosaicism are associated with megalencephaly-capillary malformation (MCAP).
PIK3CA-related overgrowth spectrum - Key Features
Congenital or early-childhood segmental, asymmetric overgrowth of adipose, muscular, fibrous, skeletal, and/or neural tissues corresponding to embryonic somatic mutation timing Low-flow and combined capillary, venous, and lymphatic vascular malformations (carrying elevated risk of painful localized intravascular coagulopathy and deep venous thrombosis/pulmonary embolism) Cutaneous epidermal nevi, lipomatous truncal masses, scoliosis, and digital anomalies (macrodactyly, wide sandal-gap toes, polydactyly) Neurologic involvement in MCAP / hemimegalencephaly subtypes: progressive megalencephaly, polymicrogyria, cerebellar tonsillar ectopia/hydrocephalus, refractory epilepsy, and developmental delay.
PIK3CA-related overgrowth spectrum - Diagnosis
Clinical recognition of patchy/asymmetric segmental overgrowth paired with vascular malformations, lipomatous masses, epidermal nevi, or megalencephaly High-depth next-generation sequencing performed directly on biopsied affected tissue (skin, overgrown fat/connective tissue, or surgical specimen; peripheral blood testing is usually false-negative due to somatic mosaicism) MRI/MRV of affected body regions (and brain MRI in MCAP) to map deep tissue overgrowth and vascular anomalies.
PIK3CA-related overgrowth spectrum - Management
Oral alpelisib (selective alpha-isoform PI3K inhibitor approved for severe PROS to shrink overgrown tissue and vascular malformations and reduce pain) Multidisciplinary vascular anomaly, orthopedic (epiphyseodesis or debulking for limb-length discrepancy), neurosurgical, and dermatologic care Coagulopathy screening (D-dimer/fibrinogen) and periprocedural anticoagulation prophylaxis for extensive venous malformations to prevent pulmonary embolism Genetic counseling reassuring families that postzygotic somatic PIK3CA mosaicism is sporadic with negligible sibling or offspring recurrence risk
McCune-Albright syndrome - Clinical Vignette
A 6-year-old girl has precocious puberty with breast development and vaginal bleeding. She has large cafe-au-lait macules with irregular "coast of Maine" borders and fibrous dysplasia of the femur.
McCune-Albright syndrome - Genetics
Postzygotic somatic mosaicism (never inherited; germline activating variants are embryonic lethal) caused by activating gain-of-function missense variants in GNAS (at p.Arg201Cys, p.Arg201His, or rarely p.Gln227) encoding the stimulatory G-protein alpha subunit (Gs-alpha). Loss of intrinsic GTPase activity locks Gs-alpha in an active GTP-bound state, driving ligand-independent constitutive cAMP overproduction across mutant bone, skin, and endocrine tissues.
McCune-Albright syndrome - Key Features
Classic clinical triad (presence of >=2 features establishes the diagnosis): Monostotic or polyostotic fibrous dysplasia of bone ("ground-glass" radiolucent lesions replacing medullary bone, proximal femur "shepherd's crook" deformity, pathologic fractures, craniofacial nerve compression, and FGF23-mediated renal phosphate wasting) Large unilateral/segmental cafe-au-lait skin macules with jagged "coast of Maine" borders respecting the midline and following lines of Blaschko Autonomous GnRH-independent peripheral precocious puberty (recurrent estrogen-producing ovarian cysts causing episodic breast development and vaginal bleeding with suppressed LH/FSH in girls) and other hyperfunctioning endocrinopathies: hyperthyroidism, GH/prolactin-secreting pituitary adenomas, and neonatal Cushing syndrome.
McCune-Albright syndrome - Diagnosis
Clinical diagnosis established by >=2 components of the classic triad (fibrous dysplasia, characteristic Blaschko-distributed "coast of Maine" cafe-au-lait macules, and autonomous endocrine hyperfunction) High-sensitivity molecular testing (such as PCR-PNA or deep NGS) performed on affected lesional bone or endocrine tissue when molecular confirmation is needed (standard peripheral blood testing is frequently negative due to mosaicism) Whole-body skeletal survey / bone scintigraphy, FGF23/serum phosphorus levels, and comprehensive baseline screening of gonadal, thyroid, pituitary (IGF-1/prolactin), and adrenal axes.
McCune-Albright syndrome - Management
Targeted medical control of autonomous endocrinopathies: aromatase inhibitors (letrozole) +/- estrogen receptor modulators/antagonists (tamoxifen, fulvestrant) for peripheral precocious puberty in girls, methimazole/thyroidectomy for hyperthyroidism, somatostatin analogs/pegvisomant for GH excess, and oral phosphate + calcitriol for FGF23-mediated hypophosphatemia Orthopedic stabilization of impending/pathologic fractures and intravenous bisphosphonates for refractory fibrous dysplasia bone pain, plus serial vision and hearing monitoring for craniofacial fibrous dysplasia Genetic counseling reassuring families that McCune-Albright syndrome is sporadic postzygotic mosaicism with zero vertical transmission and general-population sibling risk
Gestational trophoblastic disease (Hydatidiform mole) - Clinical Vignette
A patient at 10 weeks gestation has vaginal bleeding, a uterus larger than expected for dates, severe hyperemesis, and a markedly elevated beta-hCG (>100,000 mIU/mL). Ultrasound shows a "snowstorm" intrauterine pattern with no embryo and bilateral theca lutein cysts. Suction D&C cytogenetics shows 46,XX of paternal-only origin: a complete hydatidiform mole.
Gestational trophoblastic disease (Hydatidiform mole) - Genetics
Disorder of genomic imprinting driven by excess paternal vs maternal genome expression in trophoblast. Sporadic Complete Hydatidiform Mole is diploid (46,XX in ~90% via monospermic duplication of one haploid sperm in an empty ovum; 46,XY in ~10% via dispermy) and purely paternal/androgenetic, silencing maternally expressed CDKN1C (p57KIP2 negative) and carrying a 15-20% risk of malignant persistent gestational trophoblastic neoplasia (GTN). Sporadic Partial Hydatidiform Mole is diandric triploid (69,XXY, 69,XXX, or 69,XYY via dispermic fertilization of a normal haploid ovum), retains one maternal genome (p57KIP2 positive) with fetal tissue, and carries a ~1-5% GTN risk. Rare Familial Recurrent Hydatidiform Mole is an autosomal recessive maternal-effect disorder caused by biallelic maternal variants in oocyte subcortical maternal complex genes NLRP7 (40-80%) or KHDC3L, causing global maternal imprinting failure and recurrent biparental complete moles in every pregnancy regardless of partner.
Gestational trophoblastic disease (Hydatidiform mole) - Key Features
First-trimester painless vaginal bleeding (classically passing "grape-like" hydropic chorionic vesicles) and uterine size greater than gestational dates (complete mole) Markedly elevated serum beta-hCG (often >100,000 mIU/mL in complete mole) driving hCG-mediated complications: severe hyperemesis gravidarum, bilateral ovarian theca lutein cysts, biochemical hyperthyroidism (hCG cross-reacts with TSH receptor), and early-onset preeclampsia before 20 weeks gestation Classic pelvic ultrasound showing a diffuse echogenic "snowstorm" / "bunch of grapes" intrauterine mass without an embryo or amniotic fluid in complete mole (vs focal cystic placental spaces with a growth-restricted malformed triploid fetus in partial mole) Malignant progression risk (~15-20% after complete mole, ~1-5% after partial mole) to persistent GTN (invasive mole or highly chemosensitive hematogenously metastasizing choriocarcinoma, most often to the lungs).
Gestational trophoblastic disease (Hydatidiform mole) - Diagnosis
Quantitative serum beta-hCG paired with transvaginal pelvic ultrasound (and baseline chest radiograph to screen for pulmonary metastases) Definitive histopathology of evacuated uterine tissue using p57KIP2 immunohistochemistry: p57-negative in cytotrophoblast/villous stroma confirms a complete mole (absent maternal expression), whereas p57-positive staining with focal villous edema confirms a partial mole Molecular genotyping / ploidy analysis (short tandem repeats) to distinguish diploid androgenetic complete mole, triploid diandric partial mole, and diploid biparental complete mole Maternal germline sequencing of NLRP7 and KHDC3L in any patient with >=2 consecutive molar pregnancies.
Gestational trophoblastic disease (Hydatidiform mole) - Management
Uterine suction dilation and curettage (giving RhD immunoglobulin if Rh-negative; hysterectomy is an option if childbearing is complete) Mandatory post-evacuation beta-hCG surveillance: weekly serum beta-hCG until undetectable for 3 consecutive weeks, followed by monthly beta-hCG for 6 months—paired with strict reliable contraception throughout surveillance so a new pregnancy does not mask rising beta-hCG Prompt FIGO-staged chemotherapy if beta-hCG plateaus or rises (single-agent methotrexate or dactinomycin for low-risk persistent GTN; multiagent EMA-CO for high-risk GTN/choriocarcinoma) Genetic counseling: ~1-2% recurrence risk after one sporadic mole (early first-trimester ultrasound in future pregnancies), whereas women with biallelic NLRP7/KHDC3L familial recurrent moles require donor oocytes (IVF with egg donation) to achieve a normal live birth